1-9 of 9
Wenbin Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations

Wenbin Liu, Jianfeng Wu, Fan Yang, Longteng Ma, Chong Ni, Xiaomei Hou, Ling Wang, Aijing Xu, Jiahui Song, Yang Deng, Linfeng Xian, Zixiong Li, Shuo Wang, Xi Chen, Jianhua Yin, Xue Han, Chengzhong Li, Jun Zhao, Guangwen Cao
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5525–5536.
https://doi.org/10.1158/1078-0432.CCR-18-3083
Published: 13 September 2019
View article titled, Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Open the PDF for Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations in another window
Includes: Supplementary data
Journal Articles

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells

Fiona Simpkins, Kibeom Jang, Hyunho Yoon, Karina E. Hew, Minsoon Kim, Diana J. Azzam, Jun Sun, Dekuang Zhao, Tan A. Ince, Wenbin Liu, Wei Guo, Zhi Wei, Gao Zhang, Gordon B. Mills, Joyce M. Slingerland
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4874–4886.
https://doi.org/10.1158/1078-0432.CCR-17-3697
Published: 01 October 2018
View article titled, Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Open the PDF for Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells in another window
Includes: Supplementary data
Journal Articles

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Tina Cascone, Li Xu, Heather Y. Lin, Wenbin Liu, Hai T. Tran, Yuan Liu, Kathryn Howells, Vincent Haddad, Emer Hanrahan, Monique B. Nilsson, Maria A. Cortez, Uma Giri, Humam Kadara, Babita Saigal, Yun-Yong Park, Weiyi Peng, Ju-Seog Lee, Anderson J. Ryan, Juliane M. Jüergensmeier, Roy S. Herbst, Jing Wang, Robert R. Langley, Ignacio I. Wistuba, Jack J. Lee, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5489–5501.
https://doi.org/10.1158/1078-0432.CCR-16-3216
Published: 14 September 2017
View article titled, The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer
Open the PDF for The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype

Jennifer B. Dennison, Maria Shahmoradgoli, Wenbin Liu, Zhenlin Ju, Funda Meric-Bernstam, Charles M. Perou, Aysegul A. Sahin, Alana Welm, Steffi Oesterreich, Matthew J. Sikora, Robert E. Brown, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (20): 5068–5078.
https://doi.org/10.1158/1078-0432.CCR-16-0171
Published: 13 October 2016
View article titled, High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype
Open the PDF for High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-14-2888
Published: 14 June 2015
View article titled, A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Open the PDF for A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

The development of an efficient procedure for protein extraction from formalin fixed and paraffin embedded tissues and analysis of its application to reverse phase protein arrays

Huifang Guo, Wenbin Liu, Zhenlin Zhu, Eric Jonasch, Gordon B. Mills, Bryan Hennessy, Yiling Lu, Dimitra Tsavachidou
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): A12.
https://doi.org/10.1158/DIAG-10-A12
Published: 15 August 2014
View article titled, The development of an efficient procedure for protein extraction from formalin fixed and paraffin embedded tissues and analysis of its application to reverse phase protein arrays
Journal Articles

Glycogen metabolism provides nutritional support to renal cancer cells under conditions of stress and may serve as a marker of response to antiangiogenic therapy with bevacizumab

Dimitra Tsavachidou, Yang Li, Huifang Guo, Wenbin Liu, Eric Jonasch, Pheroze Tamboli, Gordon B. Mills, UT M.D.
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): PR12.
https://doi.org/10.1158/DIAG-10-PR12
Published: 15 August 2014
View article titled, Glycogen metabolism provides nutritional support to renal cancer cells under conditions of stress and may serve as a marker of response to antiangiogenic therapy with bevacizumab
Journal Articles

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

Marina Y. Konopleva, Roland B. Walter, Stefan H. Faderl, Elias J. Jabbour, Zhihong Zeng, Gautam Borthakur, Xuelin Huang, Tapan M. Kadia, Peter P. Ruvolo, Jennie B. Feliu, Hongbo Lu, LaKiesha Debose, Jan A. Burger, Michael Andreeff, Wenbin Liu, Keith A. Baggerly, Steven M. Kornblau, L. Austin Doyle, Elihu H. Estey, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2226–2235.
https://doi.org/10.1158/1078-0432.CCR-13-1978
Published: 15 April 2014
View article titled, Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia
Open the PDF for Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia in another window
Includes: Supplementary data
Journal Articles

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Victor G. Prieto, Kirk S. Culotta, Timothy L. Madden, Quanyun Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet E. Dancey, John J. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1120–1128.
https://doi.org/10.1158/1078-0432.CCR-11-2436
Published: 14 February 2012
View article titled, Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
Open the PDF for Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma in another window
Includes: Supplementary data